Toronto Ottawa Heart Summit - Heart Failure Update


Program Agenda (2021)

Who should attend:

  • Cardiovascular specialists
  • Internists
  • Allied health professionals
  • Heart failure care teams
  • Cardiovascular Trainees, Residents and Fellows
  • Basic scientist interested in CV disease
  • Primary care providers


The overall goal of this symposium is to promote the exchange of existing knowledge from innovative cellular research, through translation, to foster dissemination and collaboration, leading to better cardiovascular outcomes.

Upon completion of this program participants should be able to:

  • Recognize the changing landscape in risk factor management and implement preventative cardiology recommendations and advocate health promotion
  • Review the growing incidence of AF in the population and the impact on cognitive function
  • Review the results of two doses of Aspirin in high-risk patients with CAD
  • Evaluate new treatment options in the management of obesity
  • Discuss non-pharmacological options for AF management
  • Examine the impact of LA appendage removal on CV outcomes
  • Review of AF in patients with renal insufficiency
  • Recognize the latest diagnostic and management strategies for patients with stable coronary artery disease
  • Discuss the impact of the late-breaking trial results on coronary artery disease
  • Review appropriate management of anticoagulant and antiplatelet therapies in patients with CAD
  • Discuss evidence from late-breaking trial results in management of patients with HFpEF and HFrEF
  • Review the latest CCS heart failure guidelines and apply practical strategies into daily clinical practice
  • Understand the trajectory of advance HF challenges and treatment options
  • Review the management of patients in cardiogenic shock
  • Understand the role and limitation of surgery and minimally invasive technologies, for aortic, mitral and tricuspid valves
  • Assess the implications of recent outcomes trials for the clinical management of patients with diabetes
  • Review the updated 2021 Guidelines on risk assessment and lipid management
  • Discuss insights into the potential effects on CV outcomes with use of MRA in patients with diabetic kidney disease
  • Review new treatment options in the management of hyperkalemia in patients with HF and CKD
  • Outline appropriate cardiac surveillance plans for patients receiving cancer therapies with potential cardiac toxicities
  • Describe cardiac Amyloidosis including specific types, cardiac features and management options

Last Update: September 23, 2021
Day 1

Friday, September 24, 2021

  THEME: Resolving 0ngoing Controversies in Cardiovascular Disease
11:15 Welcome Remarks
Drs. Peter Liu and Michael Farkouh
11:30 KEYNOTE PRESENTATION: Towards More Patient-Centered Cardiovascular Care: The Role of PROs in Clinical Trials, Clinical Care and Quality Assessment
Dr. John Spertus
12:00 Discussion
12:10 Health Break
12:25-1:50 Session 1: Prevention
Chairs: Drs. Jacob Udell and Thais Coutinho
12:25 Case Presentation - Dr. Amelie Paquin
12:30 How to Prevent AF Including Cognitive Impairment
Dr. Mehrdad Golian
12:45 Aspirin in Primary and Secondary Prevention: Indication and Dosing
Dr. Guillaume Marquis-Gravel
1:00 Tai Chi and Cardiopulmonary Health
Dr. Gloria Yeh
1:15 Obesity Management
Dr. Satya Dash
1:30 Panel Discussion
1:50 Health Break
2:00-3:10 Session 2: Atrial Fibrillation
Chair: Dr. Atul Verma
2:00 Case Presentation - Dr. Vinay Garg
2:05 LAAOSIII: Left Atrial Occlusion Study III-LAA Occlusion During Cardiac Surgery Improves Outcomes
Dr. Richard Whitlock
2:20 Atrial Ablation for Heart Failure
Dr. Anthony Tang
2:35 Atrial Fibrillation & Renal Insufficiency
Dr. Atul Verma
2:50 Panel Discussion
3:10 Health Break
3:25-4:45 Session 3: Intervention/ACS
Chair: Drs. Jean-Francois Tanguay & Mina Madan
3:25 Case Presentation - Dr. Zeeshan Ahmed
Dr. Marc Pfeffer
3:45 Achieving COMPLETE Revascularization in Patients with Acute Coronary Syndromes
Dr. Shamir Mehta
4:00 Oral Antithrombotic Therapy in Coronary Artery Disease Patients: Antiplatelet(s), Anticoagulant, or Both?
Dr. Derek So
4:15 Reducing Residual Risk in Coronary Artery Disease: Lipid- and Inflammation-Modifying Therapies
Dr. Shaun Goodman
4:30 Panel Discussion
4:45 Adjournment
Day 2

Saturday, September 25, 2021

  THEME: Resolving 0ngoing Controversies in Cardiovascular Disease
8:20 Welcome Remarks
Drs. Peter Liu and Michael Farkouh
8:30-9:35 Session 4: Heart Failure
Chairs: Drs. Javed Butler and Sharon Chih
8:30 Case Presentation - Dr. Varinder Randhawa
8:35 HF Guidelines Update
Dr. Peter Liu
8:50 HFrEF: Novel sGC Stimulators
Dr. Justin Ezekowitz
9:05 HFpEF EMPEROR Preserve Trial
Dr. Javed Butler
9:20 Panel Discussion
9:35 Health Break
9:45-10:55 Session 5: ADVANCED Heart Failure
Chairs: Drs. Javed Butler and Sharon Chih
9:45 Case Presentation - Dr. Ismail Raslan
9:50 Approach to Cardiogenic Shock: Clinical Risk Prediction and Management
Dr. Sharon Chih
10:05 Advance HF
Dr. Shelley Zieroth
10:20 GUIDE-IT Trial
Dr. Justin Ezekowitz
10:35 Panel Discussion
10:55 Health Break
11:15-12:30 Session 6: Valves
Chairs: Drs. Eric Horlick and Benjamin Hibbert
11:15 Case Presentation - Dr. Anthony Poulin
11:20 TAVR
Dr. Josep Rodes-Cabau
11:35 Mitral Clip-Determining Patient Eligibility and Success
Dr. Anita Asgar
11:50 Tricuspid Valve—the Forgotten Valve
Dr. Richard Cook
12:05 Panel Discussion
12:30 Health Break
1:00-3:00 Session 7: Diabetes/Lipids
Chair: Drs. Michael Farkouh and Lawrence Leiter
1:00 Case Presentation - Dr. Ameena Meerasa
1:05 The Clinical Impact of SGLT 2 Inhibitors: CV Outcomes Trial
Dr. Lawrence Leiter
1:20 GLP-1 Receptor Agonists
Dr. Satya Dash
1:35 MRA in Diabetic Kidney Disease (FIGARO-DKD)
Dr. David Cherney
1:50 Beyond PCSK9
Dr. Robert Rosenson
2:05 Lipid Guidelines Update
Dr. Glen Pearson
2:20 REDUCE IT: Time to Act for Reducing Persistent Cardiovascular Risk
Dr. George Thanassoulis
2:35 Panel Discussion
3:00 Health Break
3:30-5:00 Session 8: Systemic Disease and the Heart
Chairs: Drs. Susanna Mak and Peter Liu
3:30 Case Presentation - - Dr. David Bobrowski
3:35 New Treatment Options for Management of Hyperkalemia in HF and CKD
Dr. Phil McFarlane
3:50 Cardio-Oncology
Dr. Bonnie Ky
4:05 Amyloid Heart Disease-New Treatment Advances
Dr. Mathew Maurer
4:20 Anderson Fabry Disease: A Reversible Hypertrophic Cardiomyopathy
Dr. Mark Iwanochko
4:35 Panel Discussion
5:00 Closing Remarks & Adjournment

(click on a button to view an agenda)


About us

The Toronto Ottawa Heart Summit has held successful symposia for the last 19 years. Join us at our next event where we will celebrate our 20th anniversary.

Opt-in/Opt-out of Email Lists

In compliance with anti-spam initiatives: